Patents by Inventor Robert B. DuBridge

Robert B. DuBridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240100157
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: March 15, 2023
    Publication date: March 28, 2024
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
  • Publication number: 20240084009
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: March 22, 2023
    Publication date: March 14, 2024
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
  • Publication number: 20240026011
    Abstract: The invention relates to Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 25, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia Culp, Chad Michael May, Danielle Dettling, Jeremiah Degenhardt
  • Publication number: 20230340159
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.
    Type: Application
    Filed: February 22, 2023
    Publication date: October 26, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia A. Culp, Chad Michael May, Danielle Dettling, Jeremiah Daniel Degenhardt
  • Publication number: 20230312715
    Abstract: Provided herein are Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format, which includes a human semm albumin (HSA) domain that increases its semm half-life. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, and thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 5, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Robert B. DuBridge, Daniel J. Hicklin, Patricia A. Culp
  • Patent number: 11744892
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: September 5, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • Patent number: 11744893
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: September 5, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. DuBridge, Maia Vinogradova, Anand Panchal
  • Publication number: 20230257451
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 19, 2022
    Publication date: August 17, 2023
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • Patent number: 11685780
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen is B7H3.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: June 27, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • Patent number: 11623958
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: April 11, 2023
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan Lemon
  • Patent number: 11607453
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 21, 2023
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Patent number: 11453716
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 27, 2022
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • Publication number: 20220273794
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 1, 2022
    Inventors: Chad MAY, Robert B. DUBRIDGE, Maia VINOGRADOVA, Anand PANCHAL
  • Publication number: 20220273795
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 1, 2022
    Inventors: Chad MAY, Robert B. DUBRIDGE, Maia VINOGRADOVA, Anand PANCHAL
  • Patent number: 11406710
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 9, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • Publication number: 20220144949
    Abstract: Provided herein are compositions of conditionally activated binding proteins containing Fc regions such that the proteins target tumor antigens. Also provided are methods for coexpressing and purifying such conditionally activated binding proteins. Methods of treating cancer by administering the conditionally activated binding proteins to a patient are also described.
    Type: Application
    Filed: March 5, 2020
    Publication date: May 12, 2022
    Inventors: Robert B. DUBRIDGE, Anand PANCHAL
  • Publication number: 20210309756
    Abstract: Provided herein are methods for co-expressing and purifying conditionally activated binding proteins such as hemi-COBRAs.
    Type: Application
    Filed: August 9, 2019
    Publication date: October 7, 2021
    Inventors: Robert B. DuBridge, Maia VINOGRADOVA, Ying ZHU
  • Patent number: 11085021
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: August 10, 2021
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister, Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Publication number: 20210095047
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 1, 2021
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • Patent number: 10844134
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 24, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto